Seattle Genetics is one of the leading biotechnology institutions that carry out cancer research. The Founder, Chairman of the Board and CEO of Seattle Genetics , Clay B. Siegall, Ph. D, is a renowned scientist by training and he has played a great role in enhancing cancer therapies since inception. Due to expansive scientific knowledge, Dr. Siegall established Seattle Genetics on a firm foundation of scientific advancements, rigorous research, drug developments and his natural desire to impact positively on the lives of patients. He has led the institution to its present day status and he a key figure in the development of antibody-drug conjugates and attaining of FDA approval.
Through collaboration between Seattle Genetics and Takeda Pharmaceuticals, the ADCETRIS is now a recognized global brand that is acceptable in more than sixty countries. Additionally, Seattle Genetics is also working on a various pipeline of proprietary ADCs for control and treatment of cancer. Under the leadership of Dr. Siegall, the company has attained multiple strategic permits for the advancement of the ADC technology, which include GlaxoSmithKline, Pfizer, Genentech, and AbbVie that have generated hundreds of millions of dollars to present. More than twenty ADCs are under clinical development utilizing the Seattle Genetics’ technology across internal and external collaborator initiatives. The company has realized more than $1.2 billion through capital-raising programs that seek private and public financing, including the initial public offering.
Before the establishment of Seattle Genetics, Dr. Siegall was working with Bristol-Myers, a research institute from 1991 to 1997. He has also worked with the National Institute of Health in the National Cancer Institute from 1988 to 1991.
Besides serving as the CEO of Seattle Genetics, Dr. Siegall is an active member of the Board governing Alder BioPharmaceuticals, Ultragenyx Pharmaceuticals Washington Roundtable, and Mirna Therapeutics. Numerous achievements have made him a recipient of various awards from different institutions. He holds a B. Sc. in Zoology from the University of Maryland and a Ph. D in Genetics from George Washington University. Moreover, he holds more than fifteen patents and he has authored more than seventy publications.